← Back to All US Stocks

BAX Stock Analysis - BAXTER INTERNATIONAL INC AI Rating

BAX NYSE Surgical & Medical Instruments & Apparatus DE CIK: 0000010456
Analysis Date: Mar 19, 2026 | Data as of: 2025-12-31
AI Rating
SELL
78% Confidence

Investment Thesis

Baxter is experiencing severe profitability deterioration with negative operating and net margins despite revenue growth, indicating fundamental operational challenges rather than cyclical weakness. The company is burning shareholder value with negative ROE (-15.6%) and ROA (-4.8%), while maintaining elevated debt levels (1.54x D/E) that limit financial flexibility to address underlying issues.

BAX Strengths

  • + Positive revenue growth of 5.7% YoY demonstrates continued market demand
  • + Healthy liquidity position with 2.31x current ratio and $2.0B cash providing operational flexibility
  • + Positive operating cash flow of $845M and free cash flow of $332M showing some cash generation despite net losses

BAX Risks

  • ! Significant operating losses (-$308M) and net losses (-$957M) indicating core business profitability crisis
  • ! Deteriorating earnings per share (-47.2% YoY decline) suggests accelerating value destruction
  • ! High leverage (1.54x D/E, $9.4B long-term debt) with negative interest coverage (-1.1x) creates vulnerability if operational performance doesn't improve
  • ! Negative returns on equity and assets signal poor capital allocation and operational inefficiency

Key Metrics to Watch

BAX Financial Metrics

Revenue
$11.2B
Net Income
$-957.0M
EPS (Diluted)
$-1.87
Free Cash Flow
$332.0M
Total Assets
$20.1B
Cash Position
$2.0B

BAX Profitability Ratios

Gross Margin 30.1%
Operating Margin -2.7%
Net Margin -8.5%
ROE -15.6%
ROA -4.8%
FCF Margin 3.0%

BAX Balance Sheet & Liquidity

Current Ratio
2.31x
Quick Ratio
1.56x
Debt/Equity
1.54x
Debt/Assets
69.6%
Interest Coverage
-1.06x
Long-term Debt
$9.4B

BAX 5-Year Financial Trend

BAX 5-year financial data: Year 2021: Revenue $12.8B, Net Income $1.0B, EPS $1.93. Year 2022: Revenue $15.1B, Net Income $1.1B, EPS $2.13. Year 2023: Revenue $14.8B, Net Income $1.3B, EPS $2.53. Year 2024: Revenue $10.6B, Net Income -$2.4B, EPS $-4.83. Year 2025: Revenue $11.2B, Net Income $2.7B, EPS $5.23.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: BAXTER INTERNATIONAL INC's revenue has declined by 12% over the 5-year period, indicating business contraction. The most recent EPS of $5.23 reflects profitable operations.

BAX Growth Metrics (YoY)

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
3.0%
Free cash flow / Revenue

BAX Quarterly Performance

Quarterly financial performance data for BAXTER INTERNATIONAL INC including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q3 2025 $2.7B -$46.0M $-0.09
Q2 2025 $2.7B $91.0M $0.18
Q1 2025 $2.5B $37.0M $0.07
Q3 2024 $2.6B -$137.0M $-0.27
Q2 2024 $3.7B -$97.0M $-0.19
Q1 2024 $3.5B $37.0M $0.07
Q3 2023 $3.6B $2.4B $4.76
Q2 2023 $3.6B -$97.0M $-0.19

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

BAX Capital Allocation

Operating Cash Flow
$845.0M
Cash generated from operations
Capital Expenditures
$513.0M
Investment in assets
Dividends Paid
$348.0M
Returned to shareholders

BAX SEC Filings

Access official SEC EDGAR filings for BAXTER INTERNATIONAL INC (CIK: 0000010456)

Disclaimer: This analysis is generated by Claude AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Mar 19, 2026 | Data as of: 2025-12-31 | Powered by Claude AI